Atlas Trials

Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer

Clinical trial NCT06015035 · COMPLETED

Trial details

NCT number
NCT06015035
Sponsor
Tang-Du Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Sintilimab and Anlotinib in Combination With Chemotherapy
Start date
2021-04-01
Primary completion
2022-04-01
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.